Skip to content

Spyre Therapeutics, Inc. SYRE TX — Tenant Improvements

Discontinued — last reported Q4 '16

Similar metrics at other companies

Cytokinetics logo
CYTKPA — Tenant Improvement Reimbursements
$300K
CubeSmart logo
CUBETX — Payments To Acquire Real Estate
$9.4M
Welltower logo
WELLTexas — SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Cost Capitalized Subsequent to Acquisition, Improvements
$1.46B
Cytokinetics logo
CYTKPA — Payments For Tenant Improvements
$300K
Rexford Industrial Realty logo
REXRTenant Improvements
$205.66M+13.2%
Lineage, Inc. logo
LINETexas — Costs capitalized subsequent to acquisition
$130M+9.2%

Other financials

Income statement

See full
Revenue-
Operating income-$45.6M+14.8%
Net income-$69.0M-54.1%
EPS (diluted)-$0.74-23.3%

Balance sheet

See full
Cash & equivalents$97.2M+100%
Total debt$4.3M-9.6%
Total equity$670.8M+39.0%
Total assets$764.0M+34.1%

Cash flow

See full
Operating cash flow-$57.4M-40.0%
CapEx-
Free cash flow-$39.4M-26.8%

Valuation

See full
Market cap$7.67B+307%

Profitability

See full
Operating margin-39,428.9%-49,795pp
Net margin-52,939.7%-61,871pp
FCF margin-3,442.8%-3,807pp

Returns & leverage

See full
Return on equity-31.1%-10.7pp
Debt / equity0.1×+0.1×
Current ratio+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:TenantImprovements.

The official record: Spyre Therapeutics, Inc.’s 10-K, filed March 7, 2019, on SEC EDGAR. View the filing →

Questions, answered.

What does TX — tenant improvements mean?
The total capital spent on renovating and customizing leased properties within the TX region.
How do you interpret TX — tenant improvements?
An increase suggests significant expansion or facility upgrades, while a decrease may indicate stable infrastructure or reduced capital investment in that region.
How does TX — tenant improvements compare across companies?
Peers in the biotech sector typically report these as leasehold improvements under capital expenditures, with variations based on the scale of laboratory build-outs.